共 103 条
- [1] Díaz-Tejedor A(2021)Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression Cancers (Basel) 13 1353-8
- [2] Lorenzo-Mohamed M(2021)Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH Am J Hematol 96 E5-296
- [3] Puig N(2015)Bispecific T-cell engagers for cancer immunotherapy Immunol Cell Biol 93 290-608
- [4] García-Sanz R(2019)Bispecific antibodies: a mechanistic review of the pipeline Nat Rev Drug Discov 18 585-2060
- [5] Mateos MV(2013)B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Clin Cancer Res 19 2048-4207
- [6] Garayoa M(2020)The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models Blood Adv 4 4195-4549
- [7] Cornell R(2020)Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma Blood Adv 4 4538-896
- [8] Hari P(2021)Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma Blood 138 896-900
- [9] Tang S(2021)MM-379: MagnetisMM-1: a study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM) Clin Lymphoma Myeloma Leuk 21 S439-44
- [10] Biran N(2021)A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma Blood 138 900-1304